Ema

EU ombudsman takes issue with trial transparency moves by EMA

EU ombudsman takes issue with trial transparency moves by EMA

By Zachary Brennan

In a letter to the EMA (European Medicines Agency), the European Ombudsman Emily O'Reilly has expressed concern that a significant change of policy on trial data transparency could limit the amount of data that becomes available.

EMA Expects OK for 2.6% Fees Hike in 2013

update

EMA Expects OK for 2.6% Fees Hike in 2013

By Gareth Macdonald

Pharmaceutical firms targeting the European market should expect drug review fees to increase by 2.6 per cent from April according to the European Medicines Agency (EMA).

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All